Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Artiva Biotherapeutics, Inc.. The associated price target was raised to $15.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Emily Bodnar’s rating is based on the promising results from Artiva Biotherapeutics’ trials, which demonstrated consistent and complete B cell depletion in patients with autoimmune diseases treated with AlloNK combined with anti-CD20 monoclonal antibodies. This combination therapy showed a high level of efficacy, achieving complete B cell depletion by Day 13 in all patients, a significant improvement over treatments using either component alone.
Moreover, the safety profile of the AlloNK + RTX regimen is notably clean, with no severe adverse events related to the treatment observed among the 32 patients involved in the trials. The absence of serious complications such as cytokine release syndrome or neurotoxicity, which are common in other cell therapies, supports the potential for outpatient administration. This ease of use, combined with the therapy’s effectiveness, positions Artiva Biotherapeutics favorably in the market, justifying the Buy rating.